EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysregulation of protein SUMOylation networks in Huntington’s disease R6/2 mouse striatum

Marketta Kachemov, Vineet Vaibhav, Charlene Smith, Niveda Sundararaman, Marie Heath, Devon F Pendlebury, Andrea Matlock, Alice Lau, Eva Morozko, Ryan G Lim, Jack Reidling, Joan S Steffan und 2 weitere

Brain · 2025

DOI: 10.1093/brain/awae319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Marketta Kachemov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA. Hauptthemen laut MEDLINE: Huntington Disease, Sumoylation, Corpus Striatum. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, HD CARE, Cedars-Sinai Proteomics and Metabolomics Core.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington’s disease is a neurodegenerative disorder caused by an expanded CAG repeat mutation in the Huntingtin (HTT) gene. The mutation impacts neuronal protein homeostasis and cortical/striatal circuitry. SUMOylation is a post-translational modification with broad cellular effects including via modification of synaptic proteins. Here, we used an optimized SUMO protein-enrichment and mass spectrometry method to identify the protein SUMOylation/SUMO interaction proteome in the context of Huntington’s disease using R6/2 transgenic and non-transgenic mice. Significant changes in the enrichment of SUMOylated and SUMO-interacting proteins were observed, including those involved in presynaptic function, cytomatrix at the active zone, cytoskeleton organization and glutamatergic signalling. Mitochondrial and RNA-binding proteins also showed altered enrichment. Modified SUMO-associated pathways in Huntington’s disease tissue include clathrin-mediated endocytosis signalling, synaptogenesis signalling, synaptic long-term potentiation and SNARE signalling. To evaluate how modulation of SUMOylation might influence functional measures of neuronal activity in Huntington’s disease cells in vitro, we used primary neuronal cultures from R6/2 and non-transgenic mice. A receptor internalization assay for the metabotropic glutamate receptor 7 (mGLUR7), a SUMO-enriched protein in the mass spectrometry, showed decreased internalization in R6/2 neurons compared to non-transgenic neurons. SiRNA-mediated knockdown of the E3 SUMO ligase protein inhibitor of activated STAT1 (Pias1), which can SUMO modify mGLUR7, reduced this Huntington’s disease phenotype. In addition, microelectrode array analysis of primary neuronal cultures indicated early hyperactivity in Huntington’s disease cells, while later time points demonstrated deficits in several measurements of neuronal activity within cortical neurons. Huntington’s disease phenotypes were rescued at selected time points following knockdown of Pias1. Collectively, our results provide a mouse brain SUMOome resource and show that significant alterations occur within the post-translational landscape of SUMO-protein interactions of synaptic proteins in Huntington’s disease mice, suggesting that targeting of synaptic SUMO networks may provide a proteostatic systems-based therapeutic approach for Huntington’s disease and other neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseSumoylationCorpus StriatumAnimalsMice, TransgenicMiceHuntingtin ProteinNeuronsDisease Models, AnimalCells, CulturedReceptors, Metabotropic GlutamateMale

Stichwörter der Autor:innen

E3 SUMO ligaseHuntington’s diseasePIAS1SUMOmGLUR7proteomicssynaptic

Substanzen

Huntingtin ProteinReceptors, Metabotropic Glutamate

Autor:innen und Institutionen

  • Neurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
  • Advanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA 92868, USA.
  • Sue and Bill Gross Stem Cell Center, University of California Irvine, Irvine, CA 92697, USA.
  • Institute of Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA 92697, USA.

ORCID-Profile: Leslie M Thompson

Förderung

  • NIH HHS
  • HD CARE
  • Cedars-Sinai Proteomics and Metabolomics Core
  • Erika Glazer Endowed Chair in Women's Heart Health
  • NSF
  • NINDS NIH HHS
  • CIRM
  • NIH

Zitieren

APA

Kachemov, M., Vaibhav, V., Smith, C., Sundararaman, N., Heath, M., Pendlebury, D. F., Matlock, A., Lau, A., Morozko, E., Lim, R. G., Reidling, J., Steffan, J. S., Van Eyk, J. E., & Thompson, L. M. (2025). Dysregulation of protein SUMOylation networks in Huntington’s disease R6/2 mouse striatum. Brain. https://doi.org/10.1093/brain/awae319

Vancouver

Kachemov M, Vaibhav V, Smith C, Sundararaman N, Heath M, Pendlebury DF, et al. Dysregulation of protein SUMOylation networks in Huntington’s disease R6/2 mouse striatum. Brain. 2025. doi:10.1093/brain/awae319

BibTeX
@article{Kachemov2025,
  author = {Kachemov, Marketta and Vaibhav, Vineet and Smith, Charlene and Sundararaman, Niveda and Heath, Marie and Pendlebury, Devon F and Matlock, Andrea and Lau, Alice and Morozko, Eva and Lim, Ryan G and Reidling, Jack and Steffan, Joan S and Van Eyk, Jennifer E and Thompson, Leslie M},
  title = {Dysregulation of protein SUMOylation networks in Huntington’s disease R6/2 mouse striatum},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awae319}
}
Kostenlos starten →